Fig. 6: NSUNs as potential targets for tumor therapy.
From: NSUNs-driven dysregulation: the next frontier in targeted cancer therapy?
A The correlation analysis between NSUNs gene expression data from the CellMiner database (https://discover.nci.nih.gov/cellminer/home.do) and drug sensitivity information from the Genomics of Drug Sensitivity in Cancer (GDSC, https://www.cancerrxgene.org/) revealed a significant association between NSUNs expression and response to various anticancer agents (R > 0.36). B Core Characteristics of NSUNs-Targeted Inhibitors. Drawing on existing research on NSUNs inhibitors, this figure presents key information on current NSUNs inhibitors, including their chemical structures, screening methods, binding sites and modes, dissociation constants (Kd), half-maximal inhibitory concentrations (IC₅₀), and relevant research references. The inhibitors including Bipyridine 19 [140], NSUN2-i4(NSUNi) [83, 100], Azetidine propenamides [139] and thiamine disulfide [141].
